(GB)
CAS 1453084-37-1(CA)
MIRVETUXIMAB SORAVTANSINE(INNE)
MIRVÉTUXIMAB SORAVTANSINE(INNF)
MIRVETUXIMAB SORAVTANSINA(INNS)
MIRVETUXIMAB SORAVTANSIN(INNC)
IMMUNOGLOBULIN G1-KAPPA, ANTI-[HOMO SAPIENS FOLR1 (FOLATE RECEPTOR 1, ADULT FOLATE-BINDING PROTEIN, FBP, OVARIAN TUMOR-ASSOCIATED ANTIGEN MOV18)], CHIMERIC MONOCLONAL ANTIBOODY CONJUGATED TO MAYTANSINOID DM4; GAMMA1 HEAVY CHAIN (1-447) [MUS MUSCULUS VH (IGHV1- 37*01 -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -HOMO SAPIENS IGHG1*01, G1M17,1 (CH1 (119-216), HINGE (217-231), CH2 (232-341), CH3 (342-446), CHS K2>DEL (447)) (119- 447)], (221-218')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-218') [MUS MUSCULUS V-KAPPA (IGKV3-9*01 -IGKJ2*01) [10.3.9] (1'-111') -HOMO SAPIENS IGKC*01, KM3 (112'-218')]; DIMER (227-227'':230-230'')-BISDISULFIDE;CONJUGATED, ON AN AVERAGE OF 3 OR 4 LYSYL, TO MAYTANSINOID DM4 [N2'-DEACETYL- N2'-(4-MERCAPTO-4-METHYL-1-OXOPENTYL)-MAYTANSINE] VIA THE REDUCIBLE SULFO-SPDB LINKER [N-SUCCINIMIDYL 4-(2- PYRIDYLDITHIO)-2-SULFOBUTANOATE], RECOMMENDED INN: LIST 75(WHOM)
MIRVETUXIMABUM SORAVTANSINUM(INN)
MIRVETUXIMABUM SORAVTANSINUM – vedlejsiucinky.cz